CoChat

Preclinical development of CAT‐354, an IL‐13 neutralizing antibody, for the treatment of severe uncontrolled asthma

Open access
May, RD, Monk, PD, Cohen, ES, Manuel, D, Dempsey, F, Davis, NHE, Dodd, AJ, Corkill, DJ, Woods, J, Joberty‐Candotti, C, Conroy, LA, Koentgen, F, Martin, EC, Wilson, R, Brennan, N, Powell, J, Anderson, IK · 2012 · British Journal of Pharmacology
Cited by 102

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND PURPOSE IL‐13 is a pleiotropic Th2 cytokine considered likely to play a pivotal role in asthma. Here we describe the preclinical in vitro and in vivo characterization of CAT‐354, an IL‐13‐neutralizing IgG4 monoclonal antibody (mAb), currently in clinical development. EXPERIMENTAL APPROACH In vitro the potency, specificity and species selectivity of CAT‐354 was assayed in TF‐1 cells, human umbilical vein endothelial cells and HDLM‐2 cells. The ability of CAT‐354 to modulate disease‐relevant mechanisms was tested in human cells measuring bronchial smooth muscle calcium flux induced by histamine, eotaxin generation by normal lung fibroblasts, CD23 upregulation in peripheral blood mononuclear cells and IgE production by B cells. In vivo CAT‐354 was tested on human IL‐13‐induced air pouch inflammation in mice, ovalbumin‐sensitization and challenge in IL‐13 humanized mice and antigen challenge in cynomolgus monkeys. KEY RESULTS CAT‐354 has a 165 pM affinity for human IL‐13 and functionally neutralized human, human variant associated with asthma and atopy (R130Q) and cynomolgus monkey, but not mouse, IL‐13. CAT‐354 did not neutralize human IL‐4. In vitro CAT‐354 functionally inhibited IL‐13‐induced eotaxin production, an analogue of smooth muscle airways hyperresponsiveness, CD23 upregulation and IgE production. In vivo in humanized mouse and cynomolgus monkey antigen challenge models CAT‐354 inhibited airways hyperresponsiveness and bronchoalveolar lavage eosinophilia. CONCLUSIONS AND IMPLICATIONS CAT‐354 is a potent and selective IL‐13‐neutralizing IgG4 mAb. The preclinical data presented here support the trialling of this mAb in patients with moderate to severe uncontrolled asthma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2011.01659.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 102

Metadata

Authors
May, R., Monk, P., Cohen, E., Manuel, D., Dempsey, F., Davis, N., Dodd, A., Corkill, D., Woods, J., Joberty‐Candotti, C., Conroy, L., Koentgen, F., Martin, E., Wilson, R., Brennan, N., Powell, J., & Anderson, I.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2012-04-10
Volume
166
Issue
1
Pages
177-193
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1630159102
Cited by
102
References
2
FWCI
5.78
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical development of CAT‐354, an IL‐13 neutralizing antibody, for the treatment of severe uncontrolled asthma. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01659.x
The paper
May, R., Monk, P., Cohen, E., Manuel, D., Dempsey, F., Davis, N., Dodd, A., Corkill, D., Woods, J., Joberty‐Candotti, C., Conroy, L., Koentgen, F., Martin, E., Wilson, R., Brennan, N., Powell, J., & Anderson, I. (2012). Preclinical development of CAT‐354, an IL‐13 neutralizing antibody, for the treatment of severe uncontrolled asthma. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01659.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.